Table 1. Patients’ baseline characteristics.
| Baseline characteristics | Patients (N = 135) | |
|---|---|---|
| Age (years) (median–IQR) | 32 (27–39) | |
| Gender, n (%) | Male | 122 (90.4) |
| Female | 13 (9.6) | |
| HIV transmission, n (%) | MSM | 112 (83) |
| MSW | 20 (14.8) | |
| IDU | 3 (2.2) | |
| Country–region, n (%) | Spain | 69 (51.1) |
| Latinamerican | 53 (39.3) | |
| Europe | 6 (4.4) | |
| Others | 7 (5.2) | |
| CDC classification, n (%) | A | 125 (92.6) |
| B | 7 (5.2) | |
| C | 3 (2.2) | |
| CD4+ cells/mm3 (median–IQR) | Basal CD4+ | 469 (347–650) |
| CD4 < 200 | 3 (2.2) | |
| HIV-1 VL (c/mL), n (%) | ≥ 100,000 copies/mL | 23 (17) |
| < 100,000 copies/mL | 112 (83) | |
| Hepatitis B co-infection, n (%) | HBsAg + | 0 |
| Anti-HBc + | 32 (23.7) | |
| Anti-HBs + | 86 (63.7) | |
| Hepatitis C co-infection (IgG HCV +), n (%) | 7 (5.2) | |
| HLAB*5701 positive, n (%) | 11 (8.1) | |
| Median time from diagnosis to start of treatment (weeks) | 6 (IQR: 3–14) | |
IQR = interquartile range; MSM = Men who have sex with men; MSW = Men who have sex with women; IDU = injecting drug users; VL = viral load; HBsAg = Hepatitis B surface antigen; Anti-HBc: Antibodies to the Hepatitis B core antigen.